TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Anthem Biosciences Ltd
ANTHEM

Anthem Biosciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 72/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹873.6

Change

-12.0 (-1.36%)

Open

₹888.0

Prev. Close

₹885.6

Day High

₹890.85

Day Low

₹869.4

Volume Analysis

Traded

373,411

Delivered

184,442

Delivery %

49.39%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (22.3%)
  • •Strong operating margin (40.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (16.0%)
  • •Strong 3-year revenue growth (26.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹907.95 ₹899.4 ₹886.5 ₹877.95 ₹865.05 ₹856.5 ₹843.6
Fibonacci ₹899.4 ₹891.21 ₹886.14 ₹877.95 ₹869.76 ₹864.69 ₹856.5
Camarilla ₹879.5 ₹877.53 ₹875.57 ₹877.95 ₹871.63 ₹869.67 ₹867.7

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+36.91%

1 Week

-4.78%

1 Month

-2.94%

3 Months

+13.37%

6 Months

+31.23%

1 Year

+11.87%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹113.37

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

20.16%

Net margin 28.77% × asset turnover 0.62x × equity multiplier 1.13x

Company Overview

Sector

Healthcare

Market Cap

₹49,633 Cr

P/E (TTM)

83.6

ROE

22.3%

Book Value

₹54.2

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Anthem Biosciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.3%); strong operating margin (40.0%); promoter holding is falling. Strong 3-year EPS growth (16.0%).

TopFund Score — Fundamentals Quality

72/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

62

Valuation

1

Cash Flow

75

Corporate Governance

75

Momentum

76

Institutional Ownership

62

Business Quality

97

Risk & Volatility

87

Liquidity

79

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company's working capital requirements have reduced from 118 days to 92.3 days
  • −Stock is trading at 16.2 times its book value
  • −Promoter holding has decreased over last quarter: -3.25%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 24 Sep 24 Sep
Settlement Of Upside Sharing Arrangement 08 Sep

Settlement of upside sharing arrangement; INR 1,276.83 million paid to three principal shareholders after Viridity Tone LLP divestment.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript 27 Jul

Transcript of Earnings Conference Call held on July 22, 2026.

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 24 Jul 24 Jul
Announcement Under 22 Jul

20th AGM held July 22, 2026; shareholders approved dividend, auditor appointment, and other resolutions.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 339 525 498 483 540 550 423 611 418
Expenses + 218 330 338 288 349 332 266 344 268
Operating Profit 121 195 160 195 191 218 157 267 151
OPM % 36.0% 37.0% 32.0% 40.0% 35.0% 40.0% 37.0% 44.0% 36.0%
Other Income + 19 28 24 14 23 48 8 52 25
Interest 4 4 3 1 2 3 0 2 1
Depreciation 19 20 20 30 26 34 35 40 30
Profit before tax 118 200 161 178 186 230 130 278 145
Tax % 30.0% 19.0% 23.0% 54.0% 27.0% 24.0% 29.0% 32.0% 17.0%
Net Profit + 82 162 124 83 136 173 93 190 120
EPS in Rs 1 3 2 1 2 3 2 3 2
Raw PDF — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 633 1,103 1,231 1,057 1,419 1,845 2,124 2,002
Expenses + 451 695 666 626 914 1,173 1,290 1,209
Operating Profit 182 408 565 431 506 672 834 793
OPM % 29.0% 37.0% 46.0% 41.0% 36.0% 36.0% 39.0% 40.0%
Other Income + 21 37 49 139 63 85 131 133
Interest 20 17 10 9 10 11 7 6
Depreciation 62 62 58 64 82 89 134 138
Profit before tax 121 366 546 497 477 657 824 783
Tax % 23.0% 26.0% 26.0% 23.0% 23.0% 31.0% 28.0% —
Net Profit + 93 271 406 385 367 451 592 576
EPS in Rs 111 320 462 7 7 8 11 10
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 19.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 413 693 1,346 1,627 1,813 2,298 2,930
Borrowings + 159 100 35 126 239 113 54
Other Liabilities + 207 232 228 148 235 284 333
Total Liabilities 787 1,034 1,619 2,014 2,398 2,808 3,429
Fixed Assets + 306 361 329 449 483 705 783
CWIP 50 19 154 164 345 297 264
Investments 99 209 273 499 472 433 1,007
Other Assets + 333 445 863 902 1,099 1,373 1,374
Total Assets 787 1,034 1,619 2,014 2,398 2,808 3,429
Equity Capital 8 8 9 114 112 112 112

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 166 278 333 306 140 271 844
Cash from Investing Activity + -109 -196 -205 -376 -221 -147 -702
Cash from Financing Activity + -48 -63 181 64 -77 -136 -40
Net Cash Flow 9 18 308 -6 -158 -12 103
CFO/OP 116 85 81 98 51 64 126
Free Cash Flow 119 159 307 112 -156 12 637

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 74.69% → 71.42%
  Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 16.42% 16.34% 12.48% 12.52%
Promoters 74.69% 74.69% 74.67% 71.42%
FII 1.66% 1.37% 1.28% 2.57%
DII 7.21% 7.6% 11.55% 13.48%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Anthem Biosciences Ltd (this stock) 49,633 83.6 16.25 22.3%
Ipca Laboratories Ltd 50,650 36.9 6.28 15.7%
Glaxosmithkline Pharma Lt 47,864 45.4 21.08 45.6%
Gland Pharma Limited 47,846 41.8 4.61 10.7%
Ajanta Pharma Limited 44,229 39.0 9.78 27.1%
Global Health Limited 40,516 70.8 10.24 15.2%
Narayana Hrudayalaya Ltd. 38,040 44.1 8.38 20.5%

Which Mutual Funds Hold Anthem Biosciences Ltd?

Frequently Asked Questions about Anthem Biosciences Ltd

Community Sentiment

What are other investors saying about Anthem Biosciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.